Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969784 | 0.98 | KDM4E (0.52) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4970012 | 0.93 | KDM4E (0.48) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3863603 | 0.86 | CA1 (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL6041286 | 0.83 | KDM4E (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL26316551 | 0.83 | ALDH1A1 (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL23014971 | 0.83 | KDM4E (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL8435356 | 0.83 | KDM4E (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL9701570 | 0.82 | TDP1 (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL8661648 | 0.81 | LMNA (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL11279959 | 0.81 | TSHR (0.52) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417384-B1 | SUPERIOR IMAGING AND VISUALIZATION OF NEOPLASTIC LESIONS; TUMOR-SPECIFIC CYTOTOXIC CANCER THERAPY, DIAGNOSIS AND TREATMENT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-07-09 | — | — | US | disclosed |
| US-20020065429-A1 | Radioiodinated phospholipid ether analogs and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-05-30 | — | — | US | disclosed |
| US-6255519-B1 | RADIOLABELLED PHARMACEUTICALS AND BIOLOGICAL PROBES UEFUL IN CANCER DIAGNOSIS AND TREATMENT; IMAGING TECHNOLOGY | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2001-07-03 | — | — | US | disclosed |
| WO-1998024480-A1 | RADIOIODINATED PHOSPHOLIPID ETHER ANALOGS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065429-A1 | Radioiodinated phospholipid ether analogs and methods of using the same | PHOSPHO1, CDIPT, LPCAT3 | KDM4E 1716/4885USP2 3785/4885ALDH1A1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.